Skip to main content Accessibility help
×
Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-06T05:12:31.504Z Has data issue: false hasContentIssue false

Debate 51B - Is Pelvic Exenteration an Option for a Pelvic Recurrence of a Vulvar/Vaginal Melanoma after Previous Radiation Therapy?

No

from Section VI - Vaginal and Vulvar Cancer

Published online by Cambridge University Press:  20 July 2023

Dennis S. Chi
Affiliation:
Memorial Sloan-Kettering Cancer Center, New York
Nisha Lakhi
Affiliation:
Richmond University Medical Center, Staten Island
Nicoletta Colombo
Affiliation:
University of Milan-Bicocca
Get access

Summary

Patients with vulvovaginal melanoma should not be considered for pelvic exenteration except possibly as a last resort in very rare, highly select cases. Instead, these patients may be best treated with a combination of hypofractionated radiation therapy and immunotherapy.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2023

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Mert, I, et al. Vulvar/vaginal melanoma: an updated Surveillance Epidemiology and End Results Database review, comparison with cutaneous melanoma and significance of racial disparities. Int J Gynecol Cancer 2013;23:11181125.CrossRefGoogle ScholarPubMed
Schiavone, MB, et al. Combined immunotherapy and radiation for treatment of mucosal melanomas of the lower genital tract. Gynecol Oncol Rep 2016;16:4246.CrossRefGoogle ScholarPubMed
Salama, AKS, et al. Ipilimumab and radiation in patients with high risk resected or regionally advanced melanoma. Clin Cancer Res 2021;27(5):12871295.CrossRefGoogle ScholarPubMed
National Comprehensive Cancer Network. Melanoma: cutaneous (Version 1.2021). Available from: www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdfGoogle Scholar
Dummer, R, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicenter, open-label, randomized, phase 3 trial. Lancet Oncol 2018;19:13151327.CrossRefGoogle ScholarPubMed
Wasif, N, et al. Does metastatectomy improve survival in patients with stage IV melanoma? A cancer registry analysis of outcomes. J Surg Oncol 2011;104:111115.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×